Walk into the lobby at 333 Oyster Point Boulevard today and the company looks smaller than it used to. The Nasdaq banner is gone. The conference rooms are quieter. The receptionist will tell you, without much ceremony, that NGM Biopharmaceuticals is still here - just no longer public, no longer working on a dozen things at once, and no longer in the business of trying to be every kind of biotech at the same time.
What it is in the business of, now, is one molecule. Its name is NGM120. It blocks a signaling pair, GDF15 and its receptor GFRAL, that the human body activates when it wants you to lose weight, stop eating, or throw up. In cancer patients, this circuit is the villain behind cachexia - the brutal muscle-wasting that kills roughly a fifth of people who die from cancer. In pregnant women with hyperemesis gravidarum, it is the reason a small minority of pregnancies become medical emergencies. NGM bet the entire company that one antibody could quiet that signal in both places.
"We don't have a portfolio anymore. We have a hypothesis."- Paraphrasing a senior NGM scientist, on the post-2024 strategy
The problem they saw
The pathway nobody owns
For two decades, drugmakers chased weight gain. NGM noticed the inverse: a population of patients losing weight they could not afford to lose, with no one paying attention. Cancer cachexia has been described in medical textbooks since Hippocrates. As of this year, the U.S. Food and Drug Administration has approved a grand total of zero drugs that meaningfully reverse it. Hyperemesis gravidarum has the same uncomfortable scoreboard. A condition serious enough to hospitalize Kate Middleton during three pregnancies still has, in 2026, no targeted therapy.
The biology was hiding in plain sight. GDF15 spikes in both conditions. GFRAL, the receptor it talks to, sits in a tiny patch of brainstem real estate called the area postrema - the body's vomiting center. Block the receptor, the theory went, and you might quiet both circuits at once. Several pharma giants had looked at this pathway and walked away, calling it scientifically interesting but clinically unproven.
"Interesting but unproven is biotech for: yours if you want it."- The YesPress editorial desk
The founders' bet
2007, before the GDF15 papers were famous
NGM was founded in 2007 by three scientists with unusually long resumes for a startup. Jin-Long Chen, who became Chief Scientific Officer, spent his career building discovery engines that looked under-explored corners of biology for therapeutic targets. David Goeddel - one of Genentech's first scientists and the person responsible for some of recombinant biology's foundational programs - signed on as a co-founder. Alex DePaoli came from the clinical side, with metabolic disease as his territory.
Their bet was unfashionable. While the industry was racing toward platform technologies and computational shortcuts, NGM built what it called an "in-house discovery engine" - a slow, patient process of identifying biological pathways the rest of the field had skipped. The output was a pipeline that, at its peak, stretched from oncology to liver disease to retinal disorders. The thesis was always the same: find the broken pathway, drug it precisely, see what happens.
The Genentech genealogy
David Goeddel's involvement is not a footnote. He was Genentech's first scientist and helped clone the genes behind some of biotech's earliest blockbusters. NGM was, in part, his attempt to apply that decoding instinct to under-mapped human biology - without the pressure to chase the obvious targets first.
The product
NGM120, in detail
NGM120 is a monoclonal antibody. It binds GFRAL, the receptor side of the GDF15/GFRAL pair, and prevents the signal from completing. In Phase 1 work, more than 200 trial participants tolerated it generally well. That is a quietly important number in biotech: it means the drug is safe enough to take into harder questions.
Those harder questions are now two Phase 2 trials. The first, in cancer cachexia, tries to show that quieting GFRAL can let patients eat, hold weight, and maintain the muscle mass that keeps them strong enough to receive treatment. The second, called EMERALD, is testing NGM120 in hyperemesis gravidarum - women so debilitated by pregnancy nausea that they cannot keep down water. Both indications share a mechanism. Neither has a serious incumbent.
"One antibody, two trials, zero approved competitors. That is either focus or a single point of failure."- The same desk, being honest
A 19-year arc, in seven beats
- 2007Founded by Jin-Long Chen, David Goeddel, and Alex DePaoli in South San Francisco.
- 2014Merck deal - multi-year metabolic disease research collaboration brings cash and credibility.
- 2019IPO on Nasdaq under the ticker NGM, the rare biotech that listed without a partnership exit.
- 2021Aldafermin readout in NASH disappoints, prompting strategic narrowing.
- 2023NGM120 advances into Phase 2 across two indications.
- 2024Taken private by The Column Group in an all-cash deal at roughly $1.55/share.
- 2025Wendy Yeh, M.D. appointed Chief Medical Officer.
The proof
Capital, partners, scope
NGM has raised, by disclosed totals, around $515 million across its lifetime. Merck spent years as a research partner, paying for access to the metabolic disease pipeline. Crossover and growth investors - The Column Group most notably - put in capital across multiple rounds. The 2024 take-private deal was led by Column Group affiliate Atlas Neon Merger Sub at a valuation that frustrated some public-market shareholders and rescued a company that had been struggling to fund its narrowed focus.
What NGM is, in five rows
Relative scale, not absolute. The last row is the one to stare at.
The mission
What they say, what it means
NGM describes its mission, in five words, as translating powerful biology into life-changing medicines. The phrase is unobjectionable in the way most biotech mission statements are. What it actually means at NGM is a discipline that few peers practice: the company is willing to walk away from its own programs. Aldafermin's mediocre Phase 2 readout in NASH was a setback for an entire portfolio at most companies; at NGM, it was the start of a multi-year shrinking that ended with a single asset.
There is something almost Victorian about it - a company small enough that everyone knows what they are working on, and what they are not.
"The most dangerous biotech is the one that knows what to say no to."- An NGM board member, in a paraphrase that may be apocryphal
Why it matters tomorrow
Two trials, one verdict
If NGM120 works in cancer cachexia, the company will have introduced a therapy into a disease with no incumbents and an enormous patient population. If it works in hyperemesis gravidarum, it will have a place in obstetric practice that, frankly, almost no biotech ever earns. If both work, NGM gets to write the playbook on a pathway it spent 19 years investigating. If neither works, the take-private deal will be a quiet eulogy.
The verdicts are coming - readouts of this kind are typically tracked in months, not years.
Back to the lobby
Walk back into 333 Oyster Point Boulevard a year from now and the company may look different again. The receptionist may have a new logo behind her, or none at all. The work, however, is the same as it was in 2007 - a small team trying to drug a pathway most of the industry overlooked. The bet is just clearer now.
NGM Biopharmaceuticals went public, went private, and along the way got smaller in headcount and larger in conviction. That is not a turnaround. It is a company that figured out what it was for.